Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer

Spring, L; Bardia, A

Bardia, A (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.

CLINICAL CANCER RESEARCH, 2018; 24 (13): 2981

Abstract

Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for h......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索